Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORER: Avapritinib in Advanced Systemic Mastocytosis
NCT02561988Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Mar 2016
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of avapritinib in systemic mastocytosis (SM) and Myeloid malignancy, sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose, Adverse Events at 24 months and 1 more. Started Mar 2016; status: completed.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis (SM)Myeloid malignancy
Beyond the preview
Go deeper on NCT02561988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561988.